<!DOCTYPE html>
<html>
<head>
  <title>Adaptive Trial Designs for Public and Global Health</title>

  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="chrome=1">
  <meta name="generator" content="pandoc" />



  <meta name="date" content="2023-09-28" />

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">

  <base target="_blank">

  <script type="text/javascript">
    var SLIDE_CONFIG = {
      // Slide settings
      settings: {
                title: 'Adaptive Trial Designs for Public and Global Health',
                        subtitle: '<em>Vaccine and Cluster Randomized Trials go Bayesian</em>',
                useBuilds: true,
        usePrettify: true,
        enableSlideAreas: true,
        enableTouch: true,
                        favIcon: 'Bayesian_Adaptive_GH_Designs_APT_Talk_files/logo.png',
              },

      // Author information
      presenters: [
            {
        name:  '<strong>Ofir Harari</strong> <a href="mailto:ofir@coreclinicalsciences.com" class="email">ofir@coreclinicalsciences.com</a> <br><br><br> <strong>Adaptive Platform Trial Scientific Meeting, Toronto, ON</strong><br><br>' ,
        company: '',
        gplus: '',
        twitter: '',
        www: '',
        github: ''
      },
            ]
    };
  </script>

  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/header-attrs-2.24/header-attrs.js"></script>
  <link href="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/fonts/fonts.css" rel="stylesheet" />
  <link href="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/theme/css/default.css" rel="stylesheet" />
  <link href="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/theme/css/phone.css" rel="stylesheet" />
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/modernizr.custom.45394.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/prettify/prettify.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/prettify/lang-r.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/prettify/lang-yaml.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/hammer.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/slide-controller.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/ioslides-13.5.1/js/slide-deck.js"></script>
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/kePrint-0.0.1/kePrint.js"></script>
  <link href="Bayesian_Adaptive_GH_Designs_APT_Talk_files/lightable-0.0.1/lightable.css" rel="stylesheet" />
  <link href="Bayesian_Adaptive_GH_Designs_APT_Talk_files/bsTable-3.3.7/bootstrapTable.min.css" rel="stylesheet" />
  <script src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/bsTable-3.3.7/bootstrapTable.js"></script>

  <style type="text/css">

    b, strong {
      font-weight: bold;
    }

    em {
      font-style: italic;
    }

    summary {
      display: list-item;
    }

    details > summary > p:only-child {
      display: inline;
    }

    slides > slide {
      -webkit-transition: all 0.4s ease-in-out;
      -moz-transition: all 0.4s ease-in-out;
      -o-transition: all 0.4s ease-in-out;
      transition: all 0.4s ease-in-out;
    }

    .auto-fadein {
      -webkit-transition: opacity 0.6s ease-in;
      -webkit-transition-delay: 0.4s;
      -moz-transition: opacity 0.6s ease-in 0.4s;
      -o-transition: opacity 0.6s ease-in 0.4s;
      transition: opacity 0.6s ease-in 0.4s;
      opacity: 0;
    }
/* https://github.com/ropensci/plotly/pull/524#issuecomment-468142578 */
slide:not(.current) .plotly.html-widget{
  display: block;
}

    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
            
    slides > slide:not(.nobackground):before {
      font-size: 12pt;
      content: "";
      position: absolute;
      bottom: 20px;
      left: 60px;
      background: url(Bayesian_Adaptive_GH_Designs_APT_Talk_files/logo.png) no-repeat 0 50%;
      -webkit-background-size: 30px 30px;
      -moz-background-size: 30px 30px;
      -o-background-size: 30px 30px;
      background-size: 30px 30px;
      padding-left: 40px;
      height: 30px;
      line-height: 1.9;
    }
  </style>

  <link rel="stylesheet" href="style.css" type="text/css" />

</head>

<body style="opacity: 0">

<slides class="layout-widescreen">

  <slide class="title-slide segue nobackground">
        <aside class="gdbar"><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/logo.png"></aside>
        <!-- The content of this hgroup is replaced programmatically through the slide_config.json. -->
    <hgroup class="auto-fadein">
      <h1 data-config-title><!-- populated from slide_config.json --></h1>
      <h2 data-config-subtitle><!-- populated from slide_config.json --></h2>
      <p data-config-presenter><!-- populated from slide_config.json --></p>
            <p style="margin-top: 6px; margin-left: -2px;">September 28, 2023</p>
          </hgroup>
  </slide>

<style type="text/css">
.reduceTopMarginText p:first-of-type {
  margin-top: -25px
}



ul {
  list-style-type: none;
  padding: 0;
}


ul > li:before {
  content: "\2B9A";
  font-size: 1.5em;
  display: inline-block;
  width: 1em;
  margin-left: -1em;
}


.title-slide hgroup h1 {
  font-size: 36px;
  letter-spacing: 0;
}


li {
  padding-bottom: 20px; /* Increase the spacing between list items */
}

</style>

<slide class="segue dark nobackground level1"><hgroup class = 'auto-fadein'><h2>Background</h2></hgroup><article  id="background" class="smaller ">

<!-- {data-background=Title_Page.png data-background-size=cover} -->

</article></slide><slide class=""><hgroup><h2>Global and Public Health Trial Characteristics</h2></hgroup><article  id="global-and-public-health-trial-characteristics" class="smaller ">

<ul>
<li>Typically large</li>
<li>Are run for a long time</li>
<li>Multi-center, logistically challenging</li>
<li>Are funded by the taxpayer or nonprofits</li>
<li>Potentially high impact</li>
<li>Could benefit greatly from saving time and resources</li>
</ul>

</article></slide><slide class=""><hgroup><h2>Bayesian Adaptive Trial Designs</h2></hgroup><article  id="bayesian-adaptive-trial-designs" class="smaller ">

<ul>
<li>Are simulation-guided, and are therefore flexible – but also computer-intensive.</li>
<li>Consists of multiple arms and multiple stages with early arm-stopping options.</li>
<li>The decision boundaries are set for the <em>posterior probability of efficacy</em> \[p_i^{\mathrm{effic}} = \mathbb{P}\left(\text{Treatment $i$ is efficacious}\big|\text{data}\right)\] for trials testing treatments against a common control, or the <em>posterior probability of superiority</em> \[p_i^{\mathrm{sup}} = \mathbb{P}\left(\text{Treatment $i$ is the most efficacious}\big|\text{data}\right)\] for trials comparing all therapies against each other. These get updated at every interim readout.</li>
<li>Potential gains include earlier EUA application, fewer patients receiving futile treatments, fewer overall patients treated and shorter run times.</li>
</ul>

</article></slide><slide class="segue dark nobackground level1"><hgroup class = 'auto-fadein'><h2>Multi-arm, Multi-stage Vaccine Trials</h2></hgroup><article  id="multi-arm-multi-stage-vaccine-trials" class="smaller ">

</article></slide><slide class=""><hgroup><h2>Modelling Assumptions</h2></hgroup><article  id="modelling-assumptions" class="smaller ">

<ul>
<li>All arms’ case counts follow Poisson processes.</li>
<li><em>Vaccine effects</em> (VEs) are measured in terms of the rate reduction relative to control.</li>
<li>Once a certain total number of cases has been recorded, data are unblinded and case distribution across groups is analyzed.</li>
<li>Some transformation of the VEs can be shown to follow a multinomial distribution.</li>
<li>Using a conjugate Dirichlet prior distribution, the posterior distribution is also Dirichlet.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>The Main Idea</h2></hgroup><article  id="the-main-idea" class="smaller ">

<ul>
<li>If we define \[
\theta_i = \dfrac{q_i(1-\mathrm{VE}_i)}{q_{\mathrm{ctrl}} + \sum_{j=1}^Kq_j(1-\mathrm{VE}_j)},
\]</li>
</ul>

<p>where \(q_i\) is the allocation probability of the \(i^{\mathrm{th}}\) vaccine, and assign \(\boldsymbol{\theta}\) a Dirichlet prior, then \[\boldsymbol{\theta}\big|n_{1}(t),\ldots n_{K}(t), n_{\mathrm{ctrl}}(t)\] will also follow a Dirichlet distribution, where \(n_i(t)\) denotes the number of infections recorded in the \(i^{\mathrm{th}}\) vaccine group.</p>

<ul>
<li>Inference on the VEs is achievable via the back-tranform \[\mathrm{VE}_i = 1 - \dfrac{\theta_i}{\theta_{\mathrm{ctrl}}}\dfrac{q_{\mathrm{ctrl}}}{q_i}.\]</li>
</ul>

</article></slide><slide class=""><hgroup><h2>What We Did</h2></hgroup><article  id="what-we-did" class="smaller ">

<ul>
<li>Generalized the model used by Pfizer/BioNTech to any number of arms with any allocation ratio.</li>
<li>Calculated the joint VE distribution and showed that inference can be restricted to paired vaccine-placebo comparisons.</li>
<li>Proposed a principled way for choosing a prior distribution.</li>
<li>Derived closed form expressions for all inferential quantities, including \(p^{\mathrm{effic}}\).</li>
<li>We can now run 100,000 simulations in ~1 minute on a standard PC.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>Trial Design Example</h2></hgroup><article  id="trial-design-example" class="smaller ">

<ul>
<li>Three vaccine groups and a common control (placebo).</li>
<li>A \(\sqrt{3}:1:1:1\) Dunnett allocation ratio to minimize the average VE uncertainty.</li>
<li>We assume VEs of 50%, 37.5% and 25%.</li>
<li>Interim analysis take place when an average of 10.5 events are observed across the remaining arms.</li>
<li>Early stopping due to efficacy occurs if \(p^{\mathrm{effic}} &gt; 99.025\%\) at any analysis.</li>
<li>Early stopping due to futility occurs if \(p^{\mathrm{effic}} &lt; 25\%\), \(50\%\) or \(75\%\) in the first, second or third analysis, respectively.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>Prior Selection</h2></hgroup><article  id="prior-selection" class="smaller ">

<ul>
<li>Prior candidates are required to have a prior probability of efficacy of \(50\%\).</li>
<li>We compare multiple candidates and use summaries and density plots.</li>
</ul>

<div class="left" style="float:left;width:48%">
<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-5-1.png" width="528" style="display: block; margin: auto;" /></p></div>

<div class="right" style="float:right;width:48%">
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">

<thead>

<tr>

<th style="text-align:center;">

\(\alpha_{\mathrm{vax}}\)

</th>

<th style="text-align:center;">

\(\alpha_{\mathrm{ctrl}}\)

</th>

<th style="text-align:center;">

Mean

</th>

<th style="text-align:center;">

Median

</th>

<th style="text-align:center;">

95% CrI

</th>

</tr>

</thead>

<tbody>

<tr>

<td style="text-align:center;">

1.00

</td>

<td style="text-align:center;">

1.52

</td>

<td style="text-align:center;">

-2.33

</td>

<td style="text-align:center;">

0.00

</td>

<td style="text-align:center;">

[-16.85; 0.97]

</td>

</tr>

<tr>

<td style="text-align:center;">

2.00

</td>

<td style="text-align:center;">

3.24

</td>

<td style="text-align:center;">

-0.55

</td>

<td style="text-align:center;">

0.00

</td>

<td style="text-align:center;">

[-5.27; 0.88]

</td>

</tr>

<tr>

<td style="text-align:center;">

5.00

</td>

<td style="text-align:center;">

8.42

</td>

<td style="text-align:center;">

-0.17

</td>

<td style="text-align:center;">

0.00

</td>

<td style="text-align:center;">

[-2.01; 0.70]

</td>

</tr>

<tr>

<td style="text-align:center;">

15.00

</td>

<td style="text-align:center;">

25.74

</td>

<td style="text-align:center;">

-0.05

</td>

<td style="text-align:center;">

0.00

</td>

<td style="text-align:center;">

[-0.87; 0.49]

</td>

</tr>

</tbody>

</table></div>

</article></slide><slide class=""><hgroup><h2>A Sample Trial</h2></hgroup><article  id="a-sample-trial" class="smaller ">

<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-9-1.png" width="576" style="display: block; margin: auto;" /></p>

<ul>
<li>In this randomly simulated trial, the third vaccine arm was stopped for futility after two analyses</li>
<li>The first vaccine was found to be efficacious after three analyses.</li>
<li>The second vaccine arm completed four analyses without meeting the efficacy threshold.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>Posterior Inference</h2></hgroup><article  id="posterior-inference" class="smaller ">

<ul>
<li>Point and interval estimation is based on the posterior VE distribution –</li>
</ul>

<table class="table table-striped table-condensed" style="margin-left: auto; margin-right: auto;">

<thead>

<tr>

<th style="text-align:center;font-size: 12px;">

Arm

</th>

<th style="text-align:center;font-size: 12px;">

Stopping<br>reason

</th>

<th style="text-align:center;font-size: 12px;">

Analysis 1<br>cases

</th>

<th style="text-align:center;font-size: 12px;">

Analysis 2<br>cases

</th>

<th style="text-align:center;font-size: 12px;">

Analysis 3<br>cases

</th>

<th style="text-align:center;font-size: 12px;">

Analysis 4<br>cases

</th>

<th style="text-align:center;font-size: 12px;">

Efficacy

</th>

<th style="text-align:center;font-size: 12px;">

Pr(Efficacy|Data)

</th>

<th style="text-align:center;font-size: 12px;">

VE [95% CrI]

</th>

</tr>

</thead>

<tbody>

<tr>

<td style="text-align:center;font-size: 12px;">

Control

</td>

<td style="text-align:center;font-size: 12px;">

</td>

<td style="text-align:center;font-size: 12px;">

20

</td>

<td style="text-align:center;font-size: 12px;">

36

</td>

<td style="text-align:center;font-size: 12px;">

57

</td>

<td style="text-align:center;font-size: 12px;">

72

</td>

<td style="text-align:center;font-size: 12px;">

</td>

<td style="text-align:center;font-size: 12px;">

</td>

<td style="text-align:center;font-size: 12px;">

</td>

</tr>

<tr>

<td style="text-align:center;font-size: 12px;">

1

</td>

<td style="text-align:center;font-size: 12px;">

Early efficacy

</td>

<td style="text-align:center;font-size: 12px;">

4

</td>

<td style="text-align:center;font-size: 12px;">

10

</td>

<td style="text-align:center;font-size: 12px;">

15

</td>

<td style="text-align:center;font-size: 12px;">

</td>

<td style="text-align:center;font-size: 12px;">

Yes

</td>

<td style="text-align:center;font-size: 12px;">

99.8%

</td>

<td style="text-align:center;font-size: 12px;">

53.4% [20.7%; 74.2%]

</td>

</tr>

<tr>

<td style="text-align:center;font-size: 12px;">

2

</td>

<td style="text-align:center;font-size: 12px;">

End of trial

</td>

<td style="text-align:center;font-size: 12px;">

6

</td>

<td style="text-align:center;font-size: 12px;">

17

</td>

<td style="text-align:center;font-size: 12px;">

23

</td>

<td style="text-align:center;font-size: 12px;">

29

</td>

<td style="text-align:center;font-size: 12px;">

No

</td>

<td style="text-align:center;font-size: 12px;">

95.2%

</td>

<td style="text-align:center;font-size: 12px;">

29.8% [-6.3%; 54.8%]

</td>

</tr>

<tr>

<td style="text-align:center;font-size: 12px;">

3

</td>

<td style="text-align:center;font-size: 12px;">

Early futility

</td>

<td style="text-align:center;font-size: 12px;">

12

</td>

<td style="text-align:center;font-size: 12px;">

21

</td>

<td style="text-align:center;font-size: 12px;">

</td>

<td style="text-align:center;font-size: 12px;">

</td>

<td style="text-align:center;font-size: 12px;">

No

</td>

<td style="text-align:center;font-size: 12px;">

48.6%

</td>

<td style="text-align:center;font-size: 12px;">

-0.9% [-69.7%; 41.4%]

</td>

</tr>

</tbody>

</table>

<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-10-1.png" width="576" style="display: block; margin: auto;" /></p>

</article></slide><slide class=""><hgroup><h2>Operating Characteristics (100k simulations)</h2></hgroup><article  id="operating-characteristics-100k-simulations" class="smaller ">

<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">

<thead>

<tr>

<th style="text-align:center;">

Arm

</th>

<th style="text-align:center;">

VE

</th>

<th style="text-align:center;">

Power

</th>

<th style="text-align:center;">

\(\mathbb{P}(\mathrm{Stop} = 1)\)

</th>

<th style="text-align:center;">

\(\mathbb{P}(\mathrm{Stop}\leq 2)\)

</th>

<th style="text-align:center;">

\(\mathbb{P}(\mathrm{Stop}\leq 3)\)

</th>

</tr>

</thead>

<tbody>

<tr>

<td style="text-align:center;">

All

</td>

<td style="text-align:center;">

0%

</td>

<td style="text-align:center;">

2.5%

</td>

<td style="text-align:center;">

23.9%

</td>

<td style="text-align:center;">

53.2%

</td>

<td style="text-align:center;">

79.0%

</td>

</tr>

<tr>

<td style="text-align:center;">

1

</td>

<td style="text-align:center;">

50%

</td>

<td style="text-align:center;">

81.3%

</td>

<td style="text-align:center;">

17.8%

</td>

<td style="text-align:center;">

43.1%

</td>

<td style="text-align:center;">

70.9%

</td>

</tr>

<tr>

<td style="text-align:center;">

2

</td>

<td style="text-align:center;">

37.5%

</td>

<td style="text-align:center;">

50.1%

</td>

<td style="text-align:center;">

10.8%

</td>

<td style="text-align:center;">

25.9%

</td>

<td style="text-align:center;">

50.4%

</td>

</tr>

<tr>

<td style="text-align:center;">

3

</td>

<td style="text-align:center;">

25%

</td>

<td style="text-align:center;">

22.8%

</td>

<td style="text-align:center;">

10.3%

</td>

<td style="text-align:center;">

24.1%

</td>

<td style="text-align:center;">

48.2%

</td>

</tr>

</tbody>

</table>

<ul>
<li>Trial inputs were calibrated for a \(2.5\%\) type I error rate and \(\geq80\%\) power for a vaccine with \(50\%\) VE.</li>
<li>A high probability of early stopping – but not necessarily fewer doses administered.</li>
</ul>

</article></slide><slide class="segue dark nobackground level1"><hgroup class = 'auto-fadein'><h2>Adaptive Cluster Randomized Trials</h2></hgroup><article  id="adaptive-cluster-randomized-trials" class="smaller ">

</article></slide><slide class=""><hgroup><h2>Some CRT Background</h2></hgroup><article  id="some-crt-background" class="smaller ">

<ul>
<li>Trials in which the cluster (e.g., a village) is the randomization unit.</li>
<li>As an example: laying attractive toxic sugar baits outside the village to reduce malaria infections.</li>
<li>Induces two variance components: subject-to-subject and cluster-to-cluster.</li>
<li>The variance inflation is governed by the cluster size and the <em>intrucluster correlation coefficient</em> (ICC).</li>
<li>A large ICC or cluster size can significantly inflate the sample size.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>What We Did</h2></hgroup><article  id="what-we-did-1" class="smaller ">

<ul>
<li>Proposed the Poisson-Gamma mixture model for CRTs with binary endpoints.</li>
<li>Showed that some transformation of the mean event rates has conjugate beta prior distributions.</li>
<li>Established the mathematical relation between the Gamma random effect parameters and the ICC.</li>
<li>Proposed a principled way for choosing prior distributions.</li>
<li>Derived the empirical Bayes plug-in estimators for the Gamma shape parameters.</li>
<li>We can now run 100,000 simulations in ~10 minutes on a standard PC.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>Modelling Assumptions</h2></hgroup><article  id="modelling-assumptions-1" class="smaller ">

<ul>
<li><p>For reasonably large clusters of size \(n_i\), and a fairly low event rate \(r_i\), we can model \[Y_{ij}\big|r_{ij} \sim \mathrm{Poisson}\left(n_ir_{ij}\right)\] the number of cases observed in the \(j^{\mathrm{th}}\) cluster or the \(i^{\mathrm{th}}\) arm.</p></li>
<li><p>To capture cluster-to-cluster variability, we model \[r_{ij}\big|\mu_i,\phi_i\sim\mathrm{Gamma}\left(\phi_i,\mu_i/\phi_i\right),\] where \(\mu_i\) is now the mean event rate and \(\phi_i\) a shape parameter.</p></li>
<li><p>The marginal case number distribution can be shown to be negative binomial with \[p_i = \dfrac{\mu_i n_i}{\phi_i + \mu_i n_i},\] and has a conjugate Beta prior.</p></li>
</ul>

</article></slide><slide class=""><hgroup><h2>Prior Selection</h2></hgroup><article  id="prior-selection-1" class="smaller ">

<ul>
<li>All priors are subject to satisfying a pre-specified a priori mean event rate (in this case \(10\%\)), assuming an ICC (here \(0.15\) and \(0.2\)).</li>
<li>We then compare them by their summaries.</li>
</ul>

<div class="left" style="float:left;width:48%">
<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-15-1.png" width="528" style="display: block; margin: auto;" /></p></div>

<div class="right" style="float:right;width:48%">
<table class="table table-striped table-bordered" style="width: auto !important; margin-left: auto; margin-right: auto;">

<thead>

<tr>

<th style="text-align:center;">

\(\mathbb{E}[\mu]\)

</th>

<th style="text-align:center;">

\(\rho\)

</th>

<th style="text-align:center;">

\(\phi\)

</th>

<th style="text-align:center;">

\((a,b)\)

</th>

<th style="text-align:center;">

95% CrI

</th>

</tr>

</thead>

<tbody>

<tr>

<td style="text-align:center;vertical-align: middle !important;" rowspan="8">

0.10

</td>

<td style="text-align:center;vertical-align: middle !important;" rowspan="4">

0.15

</td>

<td style="text-align:center;vertical-align: middle !important;" rowspan="4">

0.74

</td>

<td style="text-align:center;">

\((2.00, 1.30)\)

</td>

<td style="text-align:center;">

[0.22%; 46.29%]

</td>

</tr>

<tr>

<td style="text-align:center;">

\((4.00, 1.59)\)

</td>

<td style="text-align:center;">

[0.70%; 48.32%]

</td>

</tr>

<tr>

<td style="text-align:center;">

\((8.00, 2.19)\)

</td>

<td style="text-align:center;">

[1.49%; 41.25%]

</td>

</tr>

<tr>

<td style="text-align:center;">

\((16.00, 3.37)\)

</td>

<td style="text-align:center;">

[2.56%; 31.67%]

</td>

</tr>

<tr>

<td style="text-align:center;vertical-align: middle !important;" rowspan="4">

0.20

</td>

<td style="text-align:center;vertical-align: middle !important;" rowspan="4">

0.56

</td>

<td style="text-align:center;">

\((2.00, 1.22)\)

</td>

<td style="text-align:center;">

[0.18%; 42.06%]

</td>

</tr>

<tr>

<td style="text-align:center;">

\((4.00, 1.44)\)

</td>

<td style="text-align:center;">

[0.56%; 48.23%]

</td>

</tr>

<tr>

<td style="text-align:center;">

\((8.00, 1.89)\)

</td>

<td style="text-align:center;">

[1.24%; 44.36%]

</td>

</tr>

<tr>

<td style="text-align:center;">

\((16.00, 2.78)\)

</td>

<td style="text-align:center;">

[2.21%; 35.14%]

</td>

</tr>

</tbody>

</table></div>

</article></slide><slide class=""><hgroup><h2>Adaptive Design Example</h2></hgroup><article  id="adaptive-design-example" class="smaller ">

<ul>
<li>Suppose that we wish to trial three treatments</li>
<li>Assuming mean event rates of \(10\%\), \(7.5\%\) and \(5\%\)</li>
<li>A maximum number of \(550\) clusters divided into three analyses</li>
<li>Average cluster size of \(50\),</li>
<li>An arm gets stopped for futility if \(p^{\text{sup}} \leq 1.2\%\)</li>
<li>The trial gets stopped if any arm achieves \(p^{\text{sup}} &gt; 98.8\%\)</li>
<li>We simulate the data with an ICC of \(0.15\)</li>
</ul>

</article></slide><slide class=""><hgroup><h2>A Sample Trial</h2></hgroup><article  id="a-sample-trial-1" class="smaller ">

<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-21-1.png" width="576" style="display: block; margin: auto;" /></p>

<ul>
<li>Here first arm was dropped after the second analysis for futility.</li>
<li>The third treatment was found to be the superior of the three after the third analysis.</li>
</ul>

</article></slide><slide class=""><hgroup><h2>Shape Parameter Estimation via Empirical Bayes</h2></hgroup><article  id="shape-parameter-estimation-via-empirical-bayes" class="smaller ">

<ul>
<li>The negative binomial model is conditional on knowing the values of the shape parameters \(\phi_i\).</li>
<li>As plug-in estimates, we propose maximizing the log-marginal likelihood components.</li>
</ul>

<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-23-1.png" width="864" style="display: block; margin: auto;" /></p>

</article></slide><slide class=""><hgroup><h2>Posterior Estimation and Inference</h2></hgroup><article  id="posterior-estimation-and-inference" class="smaller ">

<table class="table table-striped" style="font-size: 12px; width: auto !important; margin-left: auto; margin-right: auto;">

<thead>

<tr>

<th style="text-align:center;text-align: center;">

Trt

</th>

<th style="text-align:center;text-align: center;">

Analysis 1<br>Clusters, Cases/Patients

</th>

<th style="text-align:center;text-align: center;">

Analysis 2<br>Clusters, Cases/Patients

</th>

<th style="text-align:center;text-align: center;">

Analysis 3<br>Clusters, Cases/Patients

</th>

<th style="text-align:center;text-align: center;">

Outcome

</th>

<th style="text-align:right;text-align: center;">

Mean event rate<br>[95% CrI]

</th>

</tr>

</thead>

<tbody>

<tr>

<td style="text-align:center;">

1

</td>

<td style="text-align:center;">

62, 261/3075

</td>

<td style="text-align:center;">

123, 559/6203

</td>

<td style="text-align:center;">

</td>

<td style="text-align:center;">

Early inferiority

</td>

<td style="text-align:right;">

8.9% [7.2%; 11.3%]

</td>

</tr>

<tr>

<td style="text-align:center;">

2

</td>

<td style="text-align:center;">

62, 202/3057

</td>

<td style="text-align:center;">

123, 469/6022

</td>

<td style="text-align:center;">

213, 844/10558

</td>

<td style="text-align:center;">

</td>

<td style="text-align:right;">

7.9% [6.6%; 9.6%]

</td>

</tr>

<tr>

<td style="text-align:center;">

3

</td>

<td style="text-align:center;">

62, 206/3059

</td>

<td style="text-align:center;">

123, 341/6186

</td>

<td style="text-align:center;">

213, 582/10652

</td>

<td style="text-align:center;">

Superiority

</td>

<td style="text-align:right;">

5.4% [4.3%; 6.9%]

</td>

</tr>

</tbody>

</table>

<p><img src="Bayesian_Adaptive_GH_Designs_APT_Talk_files/figure-html/unnamed-chunk-25-1.png" width="576" style="display: block; margin: auto;" /></p>

</article></slide><slide class=""><hgroup><h2>Operating Characteristics (100K Simulations)</h2></hgroup><article  id="operating-characteristics-100k-simulations-1" class="smaller ">

<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">

<thead>

<tr>

<th style="text-align:center;">

Mean<br>event rates

</th>

<th style="text-align:center;">

Mean no.<br>of clusters

</th>

<th style="text-align:center;">

% of patients<br>in Arm 1

</th>

<th style="text-align:center;">

% of patients<br>in Arm 2

</th>

<th style="text-align:center;">

% of patients<br>in Arm 3

</th>

<th style="text-align:center;">

True<br>positive rate

</th>

<th style="text-align:center;">

False<br>positive rate

</th>

</tr>

</thead>

<tbody>

<tr>

<td style="text-align:center;">

(10.0%, 7.5%, 5.0%)

</td>

<td style="text-align:center;">

412.1

</td>

<td style="text-align:center;">

20.9%

</td>

<td style="text-align:center;">

38.8%

</td>

<td style="text-align:center;">

40.3%

</td>

<td style="text-align:center;">

80.6%

</td>

<td style="text-align:center;">

0.0%

</td>

</tr>

<tr>

<td style="text-align:center;">

(10.0%, 10.0%, 10.0%)

</td>

<td style="text-align:center;">

545.7

</td>

<td style="text-align:center;">

33.3%

</td>

<td style="text-align:center;">

33.3%

</td>

<td style="text-align:center;">

33.3%

</td>

<td style="text-align:center;">

–

</td>

<td style="text-align:center;">

2.0%

</td>

</tr>

<tr>

<td style="text-align:center;">

(10.0%, 5.0%, 5.0%)

</td>

<td style="text-align:center;">

532.0

</td>

<td style="text-align:center;">

13.0%

</td>

<td style="text-align:center;">

43.5%

</td>

<td style="text-align:center;">

43.5%

</td>

<td style="text-align:center;">

–

</td>

<td style="text-align:center;">

9.7%

</td>

</tr>

</tbody>

</table>

<ul>
<li>Note that the &ldquo;null hypothesis&rdquo; here includes every scenario where there is no clear-cut winner.</li>
<li>&ldquo;False positives&rdquo; include detection of one of two equally effective treatments.</li>
<li>For a &ldquo;true positive&rdquo;, we must not only detect difference but also declare the correct winner.</li>
<li>In a standard trial, the 1-2 comparison alone at the 5% level (one-sided) would require 528 clusters.</li>
<li>Also note the proportion of patients receiving the worst treatment.</li>
</ul>

</article></slide><slide class="segue dark nobackground level1"><hgroup class = 'auto-fadein'><h2>Concluding Remarks</h2></hgroup><article  id="concluding-remarks" class="smaller ">

</article></slide><slide class=""><hgroup><h2>Famous Last Words</h2></hgroup><article  id="famous-last-words" class="smaller ">

<ul>
<li>Global health trials could use every bit of efficiency.</li>
<li>Adaptive trial designs provide just that – but require many simulation runs.</li>
<li>We propose innovative, MCMC-free, Bayesian vaccine and cluster randomized trial designs.</li>
<li>Response adaptive randomization (RAR) is unlikely to be applicable here.</li>
<li>Consider time to outcome and enrollment rate: could your trial benefit from adaptations?</li>
<li>Possible extensions: time-varying VE; stepped-wedge CRTs.</li>
<li>Ask us for the preprint!</li>
</ul>

<p><br> <br> <span style="color: DarkBlue; text-align: center; display: block;">
<font size="40"> <strong>Thank you!</strong> </font></span></p>

</article></slide><slide class="segue dark nobackground level1"><hgroup class = 'auto-fadein'><h2>Bibliography</h2></hgroup><article  id="bibliography" class="smaller ">

</article></slide><slide class=""><hgroup><h2>References</h2></hgroup><article  id="references" class="smaller unnumbered">

<div id="refs" class="references csl-bib-body" line-spacing="2">
<div id="ref-Hayes2017" class="csl-entry">
<p><span class="csl-left-margin">
1. </span><span class="csl-right-inline">
Hayes, R. J. &amp; Moulton, L. H. <em>Cluster randomised trials</em>. (Chapman; Hall/CRC, 2017).</span></p></div>

<div id="ref-Laurent2012" class="csl-entry">
<p><span class="csl-left-margin">
2. </span><span class="csl-right-inline">
Laurent, Stéphane &amp; Legrand, Catherine. A bayesian framework for the ratio of two poisson rates in the context of vaccine efficacy trials. <em>ESAIM: PS</em> <strong>16</strong>, 375–398 (2012).</span></p></div>

<div id="ref-Senn2022" class="csl-entry">
<p><span class="csl-left-margin">
3. </span><span class="csl-right-inline">
Senn, S. The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy. <em>Pharmaceutical Statistics</em> <strong>21</strong>, 790–807 (2022).</span></p></div>

<div id="ref-Berry2010" class="csl-entry">
<p><span class="csl-left-margin">
4. </span><span class="csl-right-inline">
Berry, S. M., Carlin, B. P., Lee, J. J. &amp; Muller, P. <em>Bayesian adaptive methods for clinical trials</em>. (CRC Press, 2010).</span></p></div>

<div id="ref-FDA2019" class="csl-entry">
<p><span class="csl-left-margin">
5. </span><span class="csl-right-inline">
Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics: Guidance for industry. (2019).</span></p></div>

<div id="ref-Turner2001" class="csl-entry">
<p><span class="csl-left-margin">
6. </span><span class="csl-right-inline">
Turner, R. M., Omar, R. Z. &amp; Thompson, S. G. Bayesian methods of analysis for cluster randomized trials with binary outcome data. <em>Statistics in Medicine</em> <strong>20</strong>, 453–472 (2001).</span></p></div>

<div id="ref-Shen2022" class="csl-entry">
<p><span class="csl-left-margin">
7. </span><span class="csl-right-inline">
Shen, J., Golchi, S., Moodie, E. E. &amp; Benrimoh, D. Bayesian group sequential designs for cluster-randomized trials. <em>Stat</em> <strong>11</strong>, e487 (2022).</span></p></div>

<div id="ref-Casella1985" class="csl-entry">
<p><span class="csl-left-margin">
8. </span><span class="csl-right-inline">
Casella, G. An introduction to empirical bayes data analysis. <em>The American Statistician</em> <strong>39</strong>, 83–87 (1985).</span></p></div></div></article></slide>


  <slide class="backdrop"></slide>

</slides>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

<!-- map slide visiblity events into shiny -->
<script>
  (function() {
    if (window.jQuery) {
       window.jQuery(document).on('slideleave', function(e) {
         window.jQuery(e.target).trigger('hidden');
      });
       window.jQuery(document).on('slideenter', function(e) {
         window.jQuery(e.target).trigger('shown');
      });
    }
  })();
</script>

</body>
</html>
